Development of field-deployable and point-of-care diagnostics for high consequence pathogens using CRISPR-based diagnostics for syndromic-based panels

Funding period: 2019-2023
Lead: Jim Strong
Total GRDI funding: $400,000

Ebola virus is an example of a high consequence pathogen, being highly contagious and having high mortality rates, with no licensed vaccines or treatments available. It is of utmost importance to quickly diagnose such pathogens in order to administer appropriate patient care and isolation. The development of CRISPR-based diagnostics can provide results in a timely manner and fill this gap. Implementation of CRISPR-based diagnostics will expand response options against high consequence pathogens and will address the need for faster, cheaper, and more robust diagnostics for emerging infectious diseases of public health concern.